Update on risankizumab for the treatment of moderate to severe psoriasis (2020)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/14712598.2020.1822813
PubMed Identifier: 32933320
Publication URI: http://europepmc.org/abstract/MED/32933320
Type: Journal Article/Review
Parent Publication: Expert Opinion on Biological Therapy
Issue: 11
ISSN: 1471-2598